Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03651765 · ClinicalTrials.gov registry record · Phase 2
Long Term Extension Trial of Setmelanotide
A Phase 2 study, sponsored by Rhythm Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 205
- Enrollment target
NCT03651765 is a Phase 2 study that has completed, run by Rhythm Pharmaceuticals. The registered enrollment target is 205 participants.
The verdict
NCT03651765, a Phase 2 study, has completed, sponsored by Rhythm Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 205 participants
- Enrollment target
Study Summary
This was a long-term extension trial to study the safety and tolerability of continued setmelanotide treatment in participants who had completed a previous clinical trial on treatment with setmelanotide for obesity associated with genetic defects upstream of the Melanocortin-4 (MC4) receptor in the leptin-melanocortin pathway.
Interventions
- DRUG Setmelanotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2018-07-15 |
| Est. Completion | 2025-01-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03651765
The ClinicalTrials.gov registry entry for NCT03651765 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 205 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rhythm Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Setmelanotide is the first listed.
NCT03651765 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03651765 about?
NCT03651765 is a clinical study titled "Long Term Extension Trial of Setmelanotide". This was a long-term extension trial to study the safety and tolerability of continued setmelanotide treatment in participants who had completed a previous clinical trial on treatment with setmelanotide for obesity associated with genetic defects upstream of the Melanocortin-4 (MC4) receptor in the ...
What is the current status of trial NCT03651765?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 205 participants. The study started on 2018-07-15. Estimated completion is 2025-01-09.
What interventions are being tested in trial NCT03651765?
The interventions under investigation include: Setmelanotide (DRUG).
Who is sponsoring clinical trial NCT03651765?
This trial is sponsored by Rhythm Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.